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ABSTRACT
Background. The revised Oxford classification of diagnostic renal biopsies has been proposed to aid in the prediction of renal
outcome. We aimed to validate the histological crescents and interstitial fibrosis and tubular atrophy (IFTA) subgrouping,
and to investigate the additional value of the proportion of crescents (CatPE) in the prediction of renal outcome.
Methods. Data were retrospectively collected over 10 years, from the time of diagnosis, by systematic review of medical
records from 90 patients with renal biopsies recruited to cohorts from two hospitals in Spain. Patients were classified into
three groups for the analysis: CatPE >25% (C2), CatPE <25% (C1) and without this type of lesion (C0). The end point was renal
survival defined by either >50% reduction in glomerular filtrate rate or end-stage renal disease.
Results. Renal survival at 5 years was 90% in group C0, 81% in group C1 and 31% in group C2 (P¼0.013). The presence of
>25% crescents in the sample was associated with more severe disease when compared with <25%, as demonstrated by
more interstitial fibrotic change and by lower estimated glomerular filtration rate at diagnosis, as well as worse renal
function at 2 and 5 years. At the time of diagnosis and at 24 months, the group with IFTA >50% had poorer renal function
compared with the other groups.
Conclusions. We have confirmed the predictive value for renal survival of the revised Oxford classification in a two-centre
study. We found worse renal outcome in patients with severe tubulointerstitial fibrosis and atrophy. Patients with
Received: 15.4.2019; Editorial decision: 3.9.2019
VC The Author(s) 2019. Published by Oxford University Press on behalf of ERA-EDTA.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/
licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
For commercial re-use, please contact journals.permissions@oup.com
284
Clinical Kidney Journal, 2021, vol. 14, no. 1, 284–290
doi: 10.1093/ckj/sfz133







/ckj/article/14/1/284/5618636 by guest on 27 M
ay 2021
extracapillary lesions >25% and IFTA >50% had a worse renal prognosis due to more severe kidney injury. These results
contribute to patient stratification in immunoglobulin A nephropathy for therapeutic, epidemiological and basic research.
Keywords: CatPE, eGFR, extracapillary proliferation, glomerular filtration, IFTA, IgAN IgA nephropathy, interstitial fibrosis–
tubular atrophy
INTRODUCTION
Iimmunoglobulin A nephropathy (IgAN) is the most common pri-
mary glomerulonephritis in the world [1], with an overall incidence
of at least 2.5/100 000 of people per year in the adult population [2]
and a variable prevalence according to the geographical area.
According to the Spanish registry of glomerular diseases (GLOSEN)
its prevalence in Spain is between 13% and 15%.
The diagnosis requires a renal biopsy confirming the pres-
ence of IgA in the mesangium and glomerular capillaries [3].
Described for the first time in 1968 by Berger and Hinglais, it
is characterized by the presence of intercapillary deposits of im-
mune complexes formed in situ by IgA–IgG. This IgA is predomi-
nantly type 1 in its polymeric form and exhibits an aberrant
glycosylation pattern characterized by galactose deficiency in
the hinge region of the heavy chain. After an antigenic stimulus,
immunocomplexes are generated and deposited in the mesan-
gium, causing local inflammation, with the consequent produc-
tion of different cytokines and complement activation. The
local inflammatory response is variable and generates mesan-
gial, endocapillary and interstitial cell proliferation, and in
some cases extracapillary lesions [4–6].
Renal biopsy is not only useful for diagnosis but also allows
patient categorization by the Oxford classification, which
established mesangial hypercellularity (M), endocapillary prolif-
eration (E), segmental glomerulosclerosis (S) and moderate-to-
severe interstitial fibrosis and tubular atrophy (IFTA) (T) as
independent risk factors for a poor renal outcome. In addition,
the presence or absence of extracapillary lesions and their per-
centage must be specified [7].
KDIGO considered only very rare cases of rapidly progressive
glomerulonephritis that resembles ANCA-associated vasculitis
when crescents involve >50% of glomeruli [8]. However, most
crescentic IgAN cases have <30% of crescents, the prognosis
and treatment of which are uncertain. Crescentic lesions were
not found to have a prognostic value in the Oxford and
Validation study of the Oxford Classification for IgA nephropa-
thy (VALIGA) studies, but there was a bias for using of steroids
or immunosuppressive therapy in these patients [9]. Recently,
an analysis that combined data from the Oxford, VALIGA, China
and Japan cohorts demonstrated that crescents were predictive
of a combined event, but only in patients not receiving immu-
nosuppressive therapy. Extracapillary proliferation (CatPE)
<25% increased the risk of a >50% decline in estimated glomer-
ular filtration rate (eGFR) or end-stage renal disease (ESRD) in
patients without immunosuppressive treatment, while crescen-
tic lesions >25% increased the risk of eGFR decline or ESRD in-
dependent of treatment [10–13]. Hence, the revised Oxford
classification suggests considering C1 (1–24% of glomeruli) and
C2 (>25% glomeruli with crescents) as an independent and ro-
bust item for stratification.
We sought to validate the revised Oxford classification of
IgAN for the prediction of renal outcome in an inclusive,
two-centre Spanish cohort as opposed to a cohort selected from
clinical trial recruits. We also sought to test the additional prog-
nostic value of the number of crescents and to revisit the




This was an observational, descriptive and retrospective study
in 90 patients diagnosed with IgAN from two Spanish university
hospitals. The inclusion criteria were biopsy-proven IgAN with
pathology slides available for review, requiring a minimum of
10 glomeruli. All patients were diagnosed by renal biopsy at
Clinic Hospital and Bellvitge University Hospital between 2005
and 2015. One patient was withdrawn due to incomplete data in
the clinical history (1%).
Of note, the policy of both centres is that renal biopsy in
patients with suspected IgAN is usually indicated in cases with
microhaematuria and proteinuria >1 g/day in more than two
determinations with or without associated renal dysfunction.
Patients and data
Patients were classified into three groups according to the Haas
description: patients with extracapillary lesions (CatPE) >25%
(C2), patients with CatPE <25% (C1) and patients with the ab-
sence of this type of lesion (C0). There were no restrictions on
initial eGFR or proteinuria, and the length of follow-up was re-
quired to be 1 year, unless ESRD occurred before that time.
Patients <15 years of age, IgAN cases associated with post-
infectious glomerulonephritis, systemic lupus erythematosus,
ANCA-associated vasculitis, chronic liver disease and Henoch–
Schonlein purpura were excluded.
Evaluation of clinical parameters
Data were collected on patients’ characteristics at the time of
renal biopsy and during follow-up, including demographics, BP,
eGFR and proteinuria. Blood levels of C-reactive protein (CRP)
and IgA were also recorded in units of milligrams per litre and
grams per litre, respectively. Follow-up information was avail-
able on the use of renin–angiotensin system blocking drugs and
immunosuppressive therapy.
We estimated the eGFR using the chronic kidney disease
Epidemiology Collaboration (CKD-EPI). MAP was calculated as 1/
3(systolic BP) þ 2/3(diastolic BP). Immunosuppressive therapy
after renal biopsy was defined as treatment with any immuno-
suppressive agent, regardless of duration or dose.
The outcomes were the rate of renal function decline (slope
of eGFR) and renal survival from a combined event defined by
either >50% reduction in eGFR or ESRD (eGFR 15 mL/min/
1.73 m2).
Histological review
Two pathologists scored the biopsies using the Oxford criteria.
Mesangial proliferation was defined (M1 or M0) according to the
presence of proliferation greater or less than 50% of the
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glomeruli, defined as four or more cells in one or more mesan-
gial areas. Endocapillary proliferation is described by the letter
E; E1 specifies the presence of this parameter, E0 its absence.
The third parameter was the segmental sclerosis, described by
the letter S; S1 specifies the presence of this parameter, S0 its
absence. The last histological parameter, IFTA, was divided into
three categories: T1 25%, T2 26–50% and >50% described as T3.
The recent modification of the Oxford classification on
extracapillary lesion parameters was included. C1 describes the
presence of extracapillary lesion, C0 its absence. In addition,
the percentage of extracapillary lesions was recorded in four
grades (0¼ 0%, 1¼<25%, 2¼ 26–50%, 3¼>50%). We determined
the fraction of glomeruli with cellular or fibrocellular crescents.
A crescent was defined as extracapillary proliferation of more
than two cell layers of any size. A cellular crescent was defined
by >50% of the lesion occupied by cells, and a fibrocellular cres-
cent was defined by <50% of the lesion occupied by cells and
<90% occupied by matrix. Fibrous crescents (composed of >90%
matrix) were not considered [8–11].
Statistical analysis
Continuous and categorical variables are expressed as mean with
standard deviation and number with percentage, respectively. To
evaluate the normal distribution of the variable, the Kolmogorov–
Smirnov test was performed. The variables with normal distribu-
tion used the mean as a measure of central tendency, and stan-
dard deviation as a measure of dispersion. The data with
abnormal distribution were used as the median measure of central
tendency and the interquartile range as a measure of dispersion.
The comparison of two qualitative variables was performed using
the Chi-square test. Student’s t-test was used to compare a quanti-
tative variable and qualitative dichotomous variable, while the
ANOVA test was used to compare the quantitative variable with a
non-dichotomous qualitative variable. Regression study used the
Cox proportional hazard model and coefficients were expressed as
a hazard ratio (HR) with a 95% confidence interval (CI). Renal sur-
vival was measured from the time of biopsy and was analysed us-
ing the Kaplan–Meier method, and the equality of survival
functions was examined using the log rank test. We used Kaplan–
Meier survival curves and Cox regression to test the relation be-
tween crescents, expressed in categories, and the survival from a
combined event. The multivariate models addressed the predictive
value of crescents adjusted for covariates (initial eGFR; time aver-
aged MAP and proteinuria; and M, E, S and T lesions). Because the
presence of crescents was strongly associated with the subsequent
use of immunosuppression, we performed a priori each model for
the entire cohort plus the untreated and treated groups separately.
All P-values were two-tailed and were considered significant
when <0.05. Analyses were carried out using SPSS (version 22;
IBM SPSS, Chicago, IL, USA) and the R software (version 3.1.2;
Free Software Foundation).
RESULTS
Clinical baseline characteristics of the cohort
The main baseline characteristics of the patient cohort are
summarized in Table 1. The mean age was 45 years (16–
83 years), with a predominance of males (62, 69%). Macrohae-
maturia was present in 11% and was more frequent in group
C2. Seventy-six percent of the patients presented arterial hy-
pertension at the time of diagnosis. The mean proteinuria of
the study population was 3 g/day, and there was a trend of
higher proteinuria in the group C2. There were no differences
in IgA and CRP levels among the groups with different degrees
of CatPE.
Strikingly, there were differences in renal function at diag-
nosis related with the presence of CatPE >25%; the mean of
eGFR was 23 mL/min/1.73 m2 in group C2; 58 mL/min/1.73 m2 in
C1; and 55 mL/min/1.73 m2 in C0 (P¼ 0.001). There were no dif-
ferences in renal function between C1 and C0 group (P¼ 0.97,
95% CI 22 to 16).
Regarding treatment, the renin–angiotensin aldosterone sys-
tem blockers were used in 65.1% of patients, and immunosup-
pression was started in 45% of the patient cohort.
Renal biopsy findings
Regarding histological variables, the mean number of glomeruli
in the sample was 12. A total of 38 (49%) patients had the
Table 1. Clinical and demographic characteristics
Variables Overall (n¼ 89) C0 (n¼51) C1 (n¼ 21) C2 (n¼ 17) P-value
Follow-up, months [mean (SD)] 52 (29) 54(24) 60 (39) 37 (25) 0.04
Male (%) 62 (69) 36 (70) 15 (71) 11 (64) 0.89
Age at diagnosis, years [median (interquartile range)] 45 (16–83) 45 (18–81) 48 (20–83) 42 (16–64) 0.5
eGFR at diagnosis, mL/min/1.73 m2 [mean (SD)] 50 (33) 55 (32) 58 (30) 23 (26) 0.001
Proteinuria, g/day [mean (SD)] 3 (3.7) 3 (4.4) 2.6 (2) 3.4 (3) 0.052
HTA [n (%)] 68 (76) 40 (78) 15 (71) 13 (76) 0.64
IgA g/L [mean (SD)] 4.95 (1.88) 4 (1.2) 3.25 (1.4) 4.3 (3) 0.31
CRP, mg/L [mean (SD)] 16 (34) 12.1 (26) 21.3 (44) 23.6 (39) 0.45
Macrohaematuria [n (%)] 11 (12) 3 (5) 2 (9) 6 (35) 0.006
Kolmogorov–Smirnov test. C0, without CatPE, C1, CatPE <25%, C2, CatPE >25%. HTA, arterial hypertension.




(n¼ 89) C0 (n¼ 51) C1 (n¼ 21) C2 (n¼ 17) P-value
M1 [n (%)] 76 (85) 41 (80) 19 (90) 16 (94) 0.7
E1 [n (%)] 22 (24) 8 (15) 5 (23) 9 (52) 0.008
S1 [n (%)] 20 19 27 16 0.2
IFTA 0.38
T0 [n (%)] 12 (13) 9 (17) 3 (14) 0
T1 [n (%)] 41 (46) 23 (45) 9 (42) 9 (52)
T2 [n (%)] 19 (21) 8 (15) 5 (23) 6 (35)
T3 [n (%)] 18 (20) 11 (21) 5 (23) 2 (11)
E1, endocapillary proliferation; S1, glomerular sclerosis; M1, mesangial
proliferation.
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presence of extracapillary lesions. Table 2 shows the distribu-
tion of the MEST criteria of the Oxford classification in relation
to the percentage of crescents observed in the three groups of
the study population.
Cellular and/or fibrocellular crescents were present in 38
individuals. The presence of crescents correlated with the E le-
sion (odds ratio of E concurrent with any crescents, 5.8; 95% CI
4.4–7.4; P¼ 0.008). All the patients in the C2 subgroup had some
grade of IFTA.
Renal outcomes
As reported, at diagnosis, group C2 presented lower GFR com-
pared with C1 or C0. In the same line, at 60 months after diagno-
sis, the mean of eGFR was 15 mL/min/1.73 m2 in group C2
compared with 59 mL/min/1.73 m2 in CatPE <25% (Groups
C0 þ C1) (P¼ 0.035, 95% CI 1.4–40).
Interestingly, at 60 months, patients included in group C2
presented a doubled risk for ESRD compared with CatPE <25%,
while IFTA >50% increased five times the risk of ESRD
compared with IFTA <50%. Neither proteinuria, macrohaematu-
ria nor endocapillary proliferation was an additional risk factor
for ESRD among the comparison groups (Table 3).
Figures 1 and 2 show that there was an inverse relationship
between the percentage of CatPE and renal survival. While re-
nal survival was better when CatPE was <25%, and there were
no differences between the groups with CatPE 26–50 and
>50%. Renal survival at 5 years was 83% in the group with
CatPE <25% (C0 þ C1) and 40% in the group C2 (P¼ 0.001). The
presence of >25% crescents in the sample was associated with
more severe disease when compared with <25%, as demon-
strated by more interstitial fibrotic change and by lower GFR at
diagnosis, as well as worse renal function at 2 and 5 years. At
the time of diagnosis and at 24 months, the group with IFTA
>50% had worse renal function compared with the other groups
(Levene’s statistic of 9.5 and 7.1, P¼ 0.005 and P¼ 0.001) (Table 4).
Figure 3 shows the difference in renal survival at 60 months
follow-up in patients with IFTA >50% compared with the group
with lesions <50%.
In multivariate analysis with respect to renal survival
(Table 5), the CatPE >25% contributed a 21% increased likelihood
of the event advanced kidney disease (P¼ 0.001) and IFTA >50%
contributed a 28% increase (P¼ 0.009).
Immunosuppression
Regarding the immunosuppressive therapy, mono-therapy
with corticosteroids was prescribed in 19% of the patients
with extracapillary lesion; corticosteroids plus other drugs
were administered in 44.2% of the individuals. The use of
these medications was higher in group C2 (Table 6). The great
Table 3. Variables associated with poor renal prognosis
Variable HR (95% CI) P-value
Proteinuria 0.6 (0.3–1.2) 0.19
Macrohaematuria 3 (0.9–9) 0.052
IFTA >50% 4.9 (1.1–20) 0.03
Endocapillary proliferation 1.4 (0.3–6) 0.6
CatPE >25% 2.1 (1–4.5) 0.03
The multivariable Cox regression model.






















< 25% – censored
25–50% – censored
> 50% – censored
FIGURE 1: Kaplan–Meier survival curve with the three degrees of CatPE.
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majority of the group with extracapillary lesions >25% re-
ceived treatment with cyclophosphamide or plasma exchange,
and the difference was statistically significant with respect to
cyclophosphamide (P¼ 0.004). In patients not treated with im-
munosuppression, addition of crescents improved the ability
of the model to discriminate between patients who did or did
not experience the event 5 years after biopsy (P¼ 0.05). In con-
trast, there was no improvement to the discrimination perfor-
mance by adding crescents to the model in patients receiving
immunosuppressive therapy.
DISCUSSION
IgAN is an important cause of ESRD in young adults, with broad
clinical and histological variability and uncertain prognosis.
Furthermore, the phenotype of renal involvement in IgAN has a
major influence on survival, and the revised Oxford classifica-
tion of diagnostic renal biopsies has been proposed to aid in the
prediction of renal outcome. Crescents are the histological hall-
mark of rapid progression and severity in many glomerular
diseases. However, in IgAN their predictive value and therapeu-
tic significance are still unclear.
We aimed to validate this histological subgrouping and in-
vestigate the additional value of the proportion of crescents in
the renal biopsy for the prediction of renal outcomes in 89
patients from cohorts of two hospitals in Spain.
In common with observations by Haas et al. [10], our study
found that the extracapillary lesion is an independent factor of
worse renal prognosis at diagnosis and during follow-up to
60 months. This risk of renal dysfunction increased when
extracapillary lesions were in >25% of the glomeruli. This find-
ing was similar to that found in the studies by Serriello et al.
[14]. Contrary to our results, the studies published by Lee et al.
[15] and Zhang et al. [16] did not find that extracapillary lesions
were an independent factor of poor renal prognosis, possibly
because their patient population had a milder disease
phenotype.
In relation to the other histological variables included in the
MEST Oxford classification, we found that only the degree of
IFTA >50% was associated with poor renal prognosis. Regarding
glomerular sclerosis and the presence of endocapillary prolifer-
ation, considered in previous studies as histological parameters
of poor prognosis [17, 18], our study found no correlation be-
tween these parameters and renal function at the time of diag-
nosis and after 60 months of follow-up. The other histological
parameters showed no statistically significant differences ei-
ther. This study confirms previously described observations on
the impact of IFTA on short- and long-term renal survival. The
presence of an IFTA grade >50% was associated with a poor re-
nal outcome [19, 20].
These findings from the Spanish population are in agree-
ment with the last paper from the VALIGA study [21], which





















< 25% – censored
> 25% – censored
FIGURE 2: Kaplan–Meier survival curve in relation to degree of CatPE.
Table 4. Comparison of the degree of IFTA with renal function at di-
agnosis and after 24 months of follow-up
eGFRa IFTA (%) n Mean (SD) 95% CI P-value
Diagnosis <50 69 56 (34) 19–41 0.001
>50 18 26 (14.6)
24 months <50 57 59 (34.5) 24–47 0.002
>50 17 23 (22.9)
aeGFR (mL/min/1.73 m2). Student’s t-test.
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stated that extracapillary lesion was associated with worse re-
nal function during follow-up, finding a worse prognosis in the
group of patients without immunosuppressive treatment. The
presence of mild-and-moderate IFTA (T1 and T2) was also an in-
dependent factor of loss of renal function at 5 years of follow-
up. However, this is a rather severe cohort of IgAN patients
given that 43% presented crescents compared with 10.5% in the
VALIGA cohort [21].
Contrary to the results from Tan et al. [22], the use of immu-
nosuppressive treatment in our cohort was not associated with
better renal function at 60 months of follow-up. This may be
explained by the presence of patients in our cohort with worse
renal function at diagnosis and with a greater percentage of
extracapillary lesions compared with those in previously men-
tioned studies.
Based on all the findings confirmed in this Spanish cohort, it
seems sensible to include the precise quantification of cellular
crescents in the routine evaluation of the biopsy of patients
with IgAN, since it constitutes an independent prognostic factor
of renal survival after 2 years of the diagnosis. The evaluation of
the presence of cellular crescents in the renal biopsy is a proce-
dure very dependent on the quality of the histological
preparation and the experience of the renal pathologist.
According to the study by Bellur et al. [21], there is disagreement
when classifying the histological lesions of the MEST terms
among pathologists from different centres, especially with re-
gard to the parameters of glomerular sclerosis and active
extracapillary lesion. On the contrary, the presence of lesions
M1, E1, C1 and S1 was associated with the decision to treat with
steroids, resulting in better outcomes for the group of treated
patients.
In order to optimize the therapeutic window guided by renal
biopsy, it would be highly advisable to have an objective and
rapid method of digital pathology that allows a more objective
quantification of the number of cellular crescents.
An adequate characterization of extracapillary proliferative
lesions, in addition to the criteria of the revised Oxford classifi-
cation, would allow a pathology-based approach to IgAN. This
strategy is a step forward towards an objective evaluation of the
impact of immunomodulatory treatments using a control bi-
opsy during the follow-up and its influence on the appearance
of advanced chronic disease in this group of patients. The previ-
ously described observations on the impact of IFTA on short-
and long-term renal survival were confirmed by our study [19].





















< 50% – censored
> 50% – censored
FIGURE 3: Kaplan–Meier survival curve in relation to the degrees of IFTA.
Table 5. Independent variables of poor renal prognosis
Variable Significance Exp. (B)
95% CI Exp. (B)
Lower Upper
CatPE >25% 0.001 0.213 0.085 0.534
IFTA >50% 0.009 0.289 0.114 0.732
Multivariate Cox regression analysis.









No treatment IS [n (%)] 49 (55) 37 (72) 10 (47) 2 (11)
Corticosteroid monotherapy [n (%)] 17 (19) 9 (17) 5 (9) 3 (17)
Mycophenolate [n (%)] 13 (14) 5 (9) 4 (19) 4 (23)
Cyclophosphamide [n (%)] 11 (12) 0 3 (14) 8 (47)
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In this work, treatment received after the diagnosis was not
considered when looking at long-term renal survival, but differ-
ences in practice in the choice and duration of therapy between
centres was small. Information about follow-up renal biopsies
in IgAN is scarce, but it seems that therapy could facilitate the
partial reversal of active lesions; since chronicity progresses de-
spite treatment, the treatment received by the patients in the
study was likely to have influenced renal outcomes. The study
is limited by its retrospective design and data collection from
two centres. Although histopathological parameters on renal bi-
opsies were assessed by experienced pathologists following a
scoring protocol developed for IgAN, inter-observer variation
was not assessed. However, this has also been determined in
previous studies. Inter-observer variation for the classification
into the three categories of crescents was not assessed either.
CONCLUSIONS
In conclusion, this work shows that the classic parameters of
poor prognosis in IgAN, such as proteinuria, hypertension at di-
agnosis and age, are markers that have a lower weight when
histological lesions are well characterized. This highlights the
importance of renal biopsy not only for early diagnosis, but also
to enable individualized treatment to be administered to
patients with IgAN. Possibly, the detailed study of renal biopsy
associated with the measurement of IgG antibodies against
hypogalactosidated IgA and complement proteins may consti-
tute the future panel of prognostic biomarkers in IgAN.
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